Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2020 | Long-term intermittent use of ubrogepant to treat acute migraines

Jessica Ailani, MD, MedStar Georgetown University Hospital, Georgetown, Washington, DC, discusses the results of the Phase III extension trial (NCT02873221) evaluating ubrogepant for acute migraines. In the extension study, it was found that there were no additional safety concerns when ubrogepant was used repeatedly long term. The ability of ubrogepant to be used at 50 and 100mg as well in combination with triptans as a rescue give the patients more control and flexibility in their treatment. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.


Dr. Ailani has received honoraria for consulting from the following companies; Amgen, Abbvie, Biohaven, Eli Lilly and Company, Lundbeck, Teva, Impel, Satsuma, Theranica, Axsome, Vorso. She has received stock options from CtrlM for consulting. She has received honoraria for speaking engagements from the following companies; Abbvie, Amgen, Biohaven, Eli Lilly, Lundbeck, and Teva. Dr. Ailani’s institution has received funding for clinical trials for her work as principal investigator from the following companies; Allergan/Abbvie, Biohaven, Eli Lilly and Company, Satsuma, Zosano. She has provided advising and editorial services and received honoraria from the following journals/magazines/and companies; Current pain and headache reports, SELF, Neurology Live, and Medscape.